Dashboard
Manage Tickers

VIRX


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
02/03/2025 21:05:45

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
02/03/2025 12:05:43

why-triumph-group-shares-are-trading-higher-by-over-36-here-are-20-stocks-moving-premarket
Why Triumph Group Shares Are Trading Highe...
02/03/2025 11:10:05

12-health-care-stocks-moving-in-fridays-pre-market-session
12 Health Care Stocks Moving In Friday's P...
12/27/2024 21:05:49

castellum-viracta-therapeutics-and-3-stocks-to-watch-heading-into-friday-corrected
Castellum, Viracta Therapeutics And 3 Stoc...
12/27/2024 19:35:09

masimo-to-rally-more-than-13-here-are-5-top-analyst-forecasts-for-friday
Masimo To Rally More Than 13%? Here Are 5 ...
12/27/2024 14:03:58

us-stocks-to-open-lower-as-index-future-decline-analysts-remain-upbeat-about-santa-rally
US Stocks To Open Lower As Index Future De...
12/27/2024 12:35:24

U.S. stock futures tumbled on Friday in premarket hours after a mixed Thursday. All four index futures slipped in trade.

rodman--renshaw-downgrades-viracta-therapeutics-to-neutral-lowers-price-target-to-025
Rodman & Renshaw Downgrades Viracta Therap...
12/27/2024 12:33:17

Rodman & Renshaw downgrades Viracta Therapeutics (NASDAQ:VIRX) from Buy to Neutral and lowers the price target from $3.5 ...

why-evaxion-biotech-shares-are-trading-higher-by-around-62-here-are-20-stocks-moving-premarket
Why Evaxion Biotech Shares Are Trading Hig...
12/27/2024 10:03:48

viracta-therapeutics-plans-to-close-its-ongoing-pivotal-phase-2-clinical-trial-of-nana-val-in-relapsedrefractory-ebv--lymphomas
Viracta Therapeutics Plans To Close Its On...
12/26/2024 21:31:59

The company emphasized that its decision to voluntarily close the trial is not the result of any new safety finding.

viracta-therapeutics-board-initiates-process-to-explore-broad-range-of-strategic-alternatives
Viracta Therapeutics Board Initiates Proce...
12/26/2024 21:30:56

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
12/04/2024 21:06:10

why-marvell-technology-shares-are-trading-higher-by-around-13-here-are-20-stocks-moving-premarket
Why Marvell Technology Shares Are Trading ...
12/04/2024 10:11:00

rbc-capital-maintains-outperform-on-viracta-therapeutics-lowers-price-target-to-2
RBC Capital Maintains Outperform on Viract...
11/14/2024 17:08:54

RBC Capital analyst Gregory Renza maintains Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and lowers the price target...

viracta-therapeutics-q3-2024-gaap-eps-027-misses-024-estimate-cash-cash-equivalents-and-short-term-investments-of-approximately-211m-is-expected-to-fund-operations-late-into-the-first-quarter-of-2025
Viracta Therapeutics Q3 2024 GAAP EPS $(0....
11/13/2024 12:26:03

Viracta Therapeutics (NASDAQ:VIRX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate o...

viracta-therapeutics-to-reprioritize-resources-to-focus-on-nana-val-development-program-in-relapsed-or-refractory-ebv-positive-peripheral-t-cell-lymphoma-announces-42-force-reduction-sees-700k-in-total-expenses
Viracta Therapeutics To Reprioritize Resou...
11/06/2024 22:32:27

12-health-care-stocks-moving-in-fridays-after-market-session
12 Health Care Stocks Moving In Friday's A...
09/27/2024 20:31:00

leerink-partners-downgrades-viracta-therapeutics-to-market-perform-lowers-price-target-to-3
Leerink Partners Downgrades Viracta Therap...
08/16/2024 11:13:10

Leerink Partners analyst Andrew Berens downgrades Viracta Therapeutics (NASDAQ:VIRX) from Outperform to Market Perform and l...

rbc-capital-maintains-outperform-on-viracta-therapeutics-lowers-price-target-to-4
RBC Capital Maintains Outperform on Viract...
08/15/2024 14:55:58

RBC Capital analyst Gregory Renza maintains Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and lowers the price target...

viracta-therapeutics-shares-are-trading-higher-after-the-company-reported-better-than-expected-q2-eps-results-also-the-company-announced-its-phase-2-naval-1-trial-results-and-will-begin-a-randomized-controlled-trial-rct
Viracta Therapeutics shares are trading hi...
08/14/2024 13:22:04

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION